{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:05:34Z","timestamp":1790748334608,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clbc.2025.06.009","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T19:58:24Z","timestamp":1750967904000},"page":"658-666.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Overweight and Risk of Recurrence Following Neoadjuvant Chemotherapy in Breast Cancer"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1482-3935","authenticated-orcid":false,"given":"Anders Lerche","family":"M\u00f8ller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe","family":"Borgquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Skarping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2025.06.009_bib0001","unstructured":"World Health Organization. Breast cancer. 2024 [Accessed March 13, 2024]; Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer."},{"key":"10.1016\/j.clbc.2025.06.009_bib0002","unstructured":"World Health Organization NORDCAN. 2024; Available from: https:\/\/nordcan.iarc.fr\/en."},{"issue":"4","key":"10.1016\/j.clbc.2025.06.009_bib0003","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.clbc.2021.01.017","article-title":"Epidemiology of De Novo metastatic breast cancer","volume":"21","author":"Daily","year":"2021","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2025.06.009_bib0004","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2025.06.009_bib0005","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10549-017-4510-3","article-title":"Breast cancer recurrence, bone metastases, and visceral metastases in women with stage II and III breast cancer in Denmark","volume":"167","author":"Cronin-Fenton","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.clbc.2025.06.009_bib0006","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/jnci\/djab202","article-title":"The incidence of breast cancer recurrence 10-32 years after primary diagnosis","volume":"114","author":"Pedersen","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2025.06.009_bib0007","unstructured":"World Health Organization. Obesity and overweight. 2024. Accessed June 26, 2024. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"10.1016\/j.clbc.2025.06.009_bib0008","unstructured":"World Obesity, Sweden. 2020; Available from: https:\/\/data.worldobesity.org\/country\/sweden-207\/#data_prevalence"},{"issue":"9","key":"10.1016\/j.clbc.2025.06.009_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djv179","article-title":"Body mass index, PAM50 subtype, and outcomes in node-positive breast cancer: CALGB 9741 (Alliance)","volume":"107","author":"Ligibel","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.clbc.2025.06.009_bib0010","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41523-021-00325-6","article-title":"Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis","volume":"7","author":"Harborg","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.clbc.2025.06.009_bib0011","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41523-021-00241-9","article-title":"The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data","volume":"7","author":"Modi","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2025.06.009_bib0012","doi-asserted-by":"crossref","first-page":"181","DOI":"10.6004\/jnccn.2020.7606","article-title":"Body mass index and weight change in patients with HER2-positive early breast cancer: exploratory analysis of the ALTTO BIG 2-06 trial","volume":"19","author":"Martel","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"10.1016\/j.clbc.2025.06.009_bib0013","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.37780","article-title":"Obesity and risk of recurrence in patients with breast cancer treated with aromatase inhibitors","volume":"6","author":"Harborg","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clbc.2025.06.009_bib0014","doi-asserted-by":"crossref","first-page":"112988","DOI":"10.1016\/j.ejca.2023.112988","article-title":"Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer","volume":"191","author":"Van Baelen","year":"2023","journal-title":"Eur J Cancer"},{"issue":"23","key":"10.1016\/j.clbc.2025.06.009_bib0015","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1002\/cncr.27527","article-title":"Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer","volume":"118","author":"Sparano","year":"2012","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.clbc.2025.06.009_bib0016","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1200\/JCO.2009.27.2021","article-title":"Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial","volume":"28","author":"Sestak","year":"2010","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.clbc.2025.06.009_bib0017","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1200\/JCO.2011.40.8666","article-title":"Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial","volume":"30","author":"Ewertz","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clbc.2025.06.009_bib0018","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ijc.34320","article-title":"Postdiagnosis body fatness, recreational physical activity, dietary factors and breast cancer prognosis: global Cancer Update Programme (CUP Global) summary of evidence grading","volume":"152","author":"Tsilidis","year":"2023","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.clbc.2025.06.009_bib0019","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/ijc.34322","article-title":"Postdiagnosis body fatness, weight change and breast cancer prognosis: global Cancer Update Program (CUP global) systematic literature review and meta-analysis","volume":"152","author":"Chan","year":"2023","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2025.06.009_bib0020","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13358","article-title":"Obesity and endocrine therapy resistance in breast cancer: mechanistic insights and perspectives","volume":"23","author":"Barone","year":"2022","journal-title":"Obes Rev"},{"issue":"1","key":"10.1016\/j.clbc.2025.06.009_bib0021","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10549-022-06664-7","article-title":"Postmenopausal overweight and breast cancer risk; results from the KARMA cohort","volume":"196","author":"Klintman","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2025.06.009_bib0022","doi-asserted-by":"crossref","unstructured":"Biglia N., Peano E., Sgandurra P., et al. Body mass index (BMI) and breast cancer: impact on tumor histopathologic features, cancer subtypes and recurrence rate in pre and postmenopausal women. Gynecol Endocrinol. 2013;29(3):263\u2013267.","DOI":"10.3109\/09513590.2012.736559"},{"issue":"4","key":"10.1016\/j.clbc.2025.06.009_bib0023","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/1097-0142(20010815)92:4<720::AID-CNCR1375>3.0.CO;2-T","article-title":"Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma","volume":"92","author":"Daling","year":"2001","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2025.06.009_bib0024","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10549-018-4853-4","article-title":"Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes","volume":"171","author":"Kogawa","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.clbc.2025.06.009_bib0025","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s10549-021-06137-3","article-title":"Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study","volume":"187","author":"O\u2019Shaughnessy","year":"2021","journal-title":"Breast Cancer Res Treatm"},{"issue":"1","key":"10.1016\/j.clbc.2025.06.009_bib0026","first-page":"127","article-title":"Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast cancer","volume":"150","author":"Fontanella","year":"2015","journal-title":"Res Treatm"},{"issue":"12","key":"10.1016\/j.clbc.2025.06.009_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144359","article-title":"Beyond axillary lymph node metastasis, BMI and menopausal status are prognostic determinants for triple-negative breast cancer treated by Neoadjuvant chemotherapy","volume":"10","author":"Bonsang-Kitzis","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.clbc.2025.06.009_bib0028","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/EDE.0b013e3181577654","article-title":"The strengthening the reporting of observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"18","author":"von Elm","year":"2007","journal-title":"Epidemiology (Cambridge, Mass.)."},{"issue":"1","key":"10.1016\/j.clbc.2025.06.009_bib0029","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1186\/s12885-019-6485-4","article-title":"Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer","volume":"19","author":"Skarping","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clbc.2025.06.009_bib0030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.breast.2020.05.013","article-title":"Mammographic density changes during neoadjuvant breast cancer treatment: neoDense, a prospective study in Sweden","volume":"53","author":"Skarping","year":"2020","journal-title":"Breast (Edinburgh)"},{"issue":"1","key":"10.1016\/j.clbc.2025.06.009_bib0031","first-page":"251","article-title":"Mammographic density as an image-based biomarker of therapy response in neoadjuvant-treated breast cancer patients","volume":"32","author":"Skarping","year":"2021","journal-title":"Cancer Causes Control"},{"issue":"6","key":"10.1016\/j.clbc.2025.06.009_bib0032","doi-asserted-by":"crossref","first-page":"558","DOI":"10.4097\/kja.19087","article-title":"Multicollinearity and misleading statistical results","volume":"72","author":"Kim","year":"2019","journal-title":"Korean J Anesthesiol"},{"issue":"1","key":"10.1016\/j.clbc.2025.06.009_bib0033","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10549-012-2339-3","article-title":"Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis","volume":"137","author":"Pierobon","year":"2013","journal-title":"Breast cancer Res Treatm"},{"issue":"3","key":"10.1016\/j.clbc.2025.06.009_bib0034","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10549-023-07139-z","article-title":"Association of physical weight statuses defined by body mass index (BMI) with molecular subtypes of premenopausal breast cancer: a systematic review and meta-analysis","volume":"203","author":"Li","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.clbc.2025.06.009_bib0035","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<301::AID-CNCR12>3.0.CO;2-5","article-title":"Body mass and breast cancer. Relationship between method of detection and stage of disease","volume":"77","author":"Reeves","year":"1996","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.clbc.2025.06.009_bib0036","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1080\/0284186X.2022.2143277","article-title":"Factors associated with breast cancer mammography screening and breast self-examination in Irish women: results from the Irish Longitudinal Study on Ageing (TILDA)","volume":"61","author":"O'Sullivan","year":"2022","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clbc.2025.06.009_bib0037","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2016.02.028","article-title":"Body weight and sensitivity of screening mammography","volume":"60","author":"Njor","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2025.06.009_bib0038","doi-asserted-by":"crossref","unstructured":"Castell\u00f3 A., Ascunce N., Salas-Trejo D., et al. Association between Western and Mediterranean dietary patterns and mammographic density. Obstetr Gynecol (New York. 1953). 2016;128(3):574\u2013581.","DOI":"10.1097\/AOG.0000000000001589"},{"issue":"2","key":"10.1016\/j.clbc.2025.06.009_bib0039","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10147-014-0712-4","article-title":"Aggressive estrogen-receptor-positive breast cancer arising in patients with elevated body mass index","volume":"20","author":"Santa-Maria","year":"2015","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2025.06.009_bib0040","first-page":"305","article-title":"Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population","volume":"24","author":"Kamineni","year":"2013","journal-title":"Cancer Causes Contr"},{"issue":"25","key":"10.1016\/j.clbc.2025.06.009_bib0041","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1200\/JCO.19.01771","article-title":"Differential benefit of adjuvant Docetaxel-based chemotherapy in patients with early breast cancer according to baseline body mass index","volume":"38","author":"Desmedt","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2025.06.009_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2023.07.002","article-title":"Impact of body mass index and its change on survival outcomes in patients with early breast cancer: a pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials","volume":"71","author":"Chen","year":"2023","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.clbc.2025.06.009_bib0043","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jgo.2017.11.007","article-title":"The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436)","volume":"9","author":"Morrison","year":"2018","journal-title":"J Geriatr Oncol"},{"issue":"6","key":"10.1016\/j.clbc.2025.06.009_bib0044","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/0284186X.2022.2055976","article-title":"The association between body mass index and pathological complete response in neoadjuvant-treated breast cancer patients","volume":"61","author":"Skarping","year":"2022","journal-title":"Acta Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2025.06.009_bib0045","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s12282-020-01194-w","article-title":"Impact of body mass index on pathological complete response following neoadjuvant chemotherapy in operable breast cancer: a meta-analysis","volume":"28","author":"Wang","year":"2021","journal-title":"Breast Cancer"},{"issue":"4","key":"10.1016\/j.clbc.2025.06.009_bib0046","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1158\/1078-0432.CCR-20-3341","article-title":"Impact of body mass index on presence of ctDNA and disease recurrence after neoadjuvant chemotherapy for triple-negative breast cancer: analysis from BRE12-158","volume":"27","author":"Ballinger","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.clbc.2025.06.009_bib0047","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1093\/annonc\/mdt294","article-title":"Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis","volume":"24","author":"Hourdequin","year":"2013","journal-title":"Annals of oncology"},{"issue":"18","key":"10.1016\/j.clbc.2025.06.009_bib0048","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1200\/JCO.21.00471","article-title":"Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update","volume":"39","author":"Griggs","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2025.06.009_bib0049","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1186\/s12885-021-08343-0","article-title":"Metabolic comorbidities and the association with risks of recurrent metastatic disease in breast cancer survivors","volume":"21","author":"Anwar","year":"2021","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2025.06.009_bib0050","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1210\/er.2006-0045","article-title":"Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor Family: molecular mechanism and clinical implications for endocrine therapy resistance","volume":"29","author":"Arpino","year":"2008","journal-title":"Endocr Rev"},{"key":"10.1016\/j.clbc.2025.06.009_bib0051","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221079123","article-title":"Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications","author":"Ligorio","year":"2022","journal-title":"Therapeutic Advances in Medical Oncology"},{"key":"10.1016\/j.clbc.2025.06.009_bib0052","doi-asserted-by":"crossref","first-page":"116615","DOI":"10.1016\/j.biopha.2024.116615","article-title":"Targeting the crosstalk between estrogen receptors and membrane growth factor receptors in breast cancer treatment: advances and opportunities","volume":"175","author":"Yan","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"10.1016\/j.clbc.2025.06.009_bib0053","first-page":"1157","article-title":"The impact of body size changes on recurrence risk depends on age and estrogen receptor status in primary breast cancer","volume":"30","author":"Tryggvadottir","year":"2019","journal-title":"Cancer Causes Contr"},{"issue":"1","key":"10.1016\/j.clbc.2025.06.009_bib0054","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1186\/s12889-021-10606-1","article-title":"Long-term body mass index changes in overweight and obese adults and the risk of heart failure, cardiovascular disease and mortality: a cohort study of over 260,000 adults in the UK","volume":"21","author":"Iyen","year":"2021","journal-title":"BMC Public Health"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682092500179X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682092500179X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:18:52Z","timestamp":1758068332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152682092500179X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S152682092500179X"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2025.06.009","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overweight and Risk of Recurrence Following Neoadjuvant Chemotherapy in Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2025.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}